

RESPIRATORY SYNCYTIAL VIRUS WITH A GENOMIC DEFICIENCY COMPLEMENTED *IN TRANS*

Field of the invention

5 The present invention relates to the field of vaccination, and more specifically to vaccines against disease caused by pneumoviruses such as e.g. Respiratory Syncytial Virus (RSV). The invention pertains RSV virions carrying an RSV genome in which a gene that is essential for infectivity has been inactivated, while the corresponding wild type gene-product is complemented *in trans* to the virion. The invention further relates
10 to methods for the production of such RSV virions and to their use in vaccines and methods for vaccination against pneumoviruses.

Background of the invention

Human respiratory Syncytial virus is classified in the genus Pneumovirus, family
15 Paramyxoviruses. It is a major cause of severe lower respiratory tract disease in infants, the elderly and in immunocompromised individuals. It is also an important factor in upper respiratory tract disease in older children and adults. Currently there is no effective h-RSV vaccine available in the art.

RSV is an enveloped RNA virus that expresses two major antigens at its surface:
20 the attachment protein G and the fusion protein F. Both proteins appear to invoke protective antibodies. G is the determinant of the two known h-RSV subgroups A and B. Antigenic differences can be found within the two groups. The G protein shows a high degree of variation with only 53 % amino acid homology between groups A and B and up to 20% differences in G protein sequences within group A (Mufson 1988, Cane
25 1991).

Passive immunisation with RSV-enriched immunoglobulin (Respigam) or synthetic humanised monoclonal antibodies against F (Palivizumab) is currently used to treat and protect neonates of certain predispositions (e.g. premature birth) against RSV infection (Robinson 2000, Greenough 2000). RSV pathology has two major
30 aspects: cell damage caused by the virus itself and tissue damage caused by the overreacting immune system. The latter is a highly complicating factor in vaccine design.

RSV infections are seasonal, limited to the winter period and peak in the Northern Hemisphere around the end of the year. RSV infects every child before the age of two, in many cases twice. Older individuals on average are infected every other year, depending on the setting; people in close contact with infants and young children have a 50% risk. The virus spreads by close contact, in droplets or through contaminated surfaces. RSV is not efficiently spread through aerosols; the virus particles are relatively unstable. Internal spread of the virus from the upper respiratory tract (URT) to the lower respiratory tract (LRT) occurs predominantly by inhalation of virus particles produced in the URT epithelium during primary infection. Spread through syncytium formation (one of the pathological properties of the virus, which gave it its name) can not be ruled out and may play a secondary role in LRT infection.

In general, RSV pathology starts in the URT; the port of entry is the nose and to a lesser extent the eyes – not the mouth. When restricted to URT tissues, disease is limited to common cold, although in adults sometimes severe. However, when the virus can reach the LRT, bronchiolitis and pneumonia can ensue in unprotected individuals. In young infants, this can be life threatening, approx. 1/100 will require hospitalisation and mechanical ventilation, out of these 1% may die. In the elderly, RSV-induced LRT disease is a major cause of hospitalisation; it is suspected that RSV causes 25% of flu-like diseases.

The immune response to RSV is complex. In general, exposure to h-RSV will build up a response that protects against LRT disease. This response wanes with older age, causing the higher susceptibility to RSV of the older population. Effective long lasting protection against URT disease appears not feasible: re-infection is very common, even within the same season and this is not caused by viral variation. Protection against RSV infection involves antibodies against viral proteins F and G circulating in the blood, which can prevent LRT disease. URT infection can be controlled by mucosal antibodies against F and G, but these have a limited life span. CD8+ T cells against as yet unidentified viral proteins are required to clear the virus from infected tissues, but they appear to be short-lived or inefficiently recruited from their reservoirs. Most likely, this is caused by RSV-expressed factors, possibly encoded in the G gene (Srikiatkachorn, 1997a).

An important aspect of RSV disease is immune enhancement of pathology. In limited cases the cellular immune response can exacerbate RSV disease by the action of

cytokines on infected tissues released from excessively attracted granulocytes. Host predisposition is involved in this reaction, but possibly also the timing of first RSV infection after birth. Unfortunately, early vaccine trials with formalin-inactivated RSV showed that in these vaccination settings immune enhanced pathology upon wt
5 infection was prevalent (Kim 1969). Factors contained in RSV appear to be responsible for this phenomenon and were apparently released by formalin treatment. In the 40 years since then, it was gradually shown that the viral G protein is the predominant mediator of these problems, but the mechanism remains unclear (Srikiatkhachorn 1997b). In any case, vaccination with a G protein out of the context of the virion (i.e. in
10 inactivated virus preparations, as expression product not properly embedded in a membrane or in the form of peptides) seems to be causing immune enhancement in model systems. Thus, although G contributes to some extent to RSV immunity, its properties also complicate vaccine design.

Initial live RSV vaccine candidates included cold passaged or temperature-sensitive mutants. The former have been attenuated by culturing at decreasing
15 temperature, leading to dependency on low temperatures for growth, whereas the latter mutants have been made dependent on a specific, usually higher temperature for replication by chemical or radiation mutagenesis. These live virus vaccine candidates appeared to be either under- or overattenuated (Crowe 1998).

20 Subunit vaccine candidates are derived from either the RSV-F or the G protein, being the main targets for neutralising antibodies. A candidate subunit vaccine, PFP2, purified F protein, is safe in RSV-seropositive patients, but it did not provide full protection against LRT infection and associated disease (Gonzalez 2000). Another subunit vaccine approach is BBG2Na, which consists of a polypeptide, comprising
25 amino acid 130-230 of h-RSV-G, fused to the albumin-binding domain of streptococcal G protein (Power 1997). BBG2Na induces a T helper type 2 response in neonatal mice, and does not elicit lung immunopathology (Siegrist 1999). There is no data yet on protection. The use of new adjuvants for a balanced humoral and cellular immune response are currently under investigation in animal models (Plotnicky 2003).

30 The use of plasmid-DNA vectors encoding RSV-F and G antigens as vaccine candidates has been studied in animal models. These vaccines induce protective responses in rodents (Li 2000), but in one study RSV-F DNA vaccine candidate immunised mice developed a slightly enhanced pulmonary inflammatory response

following challenge with wt virus (Bembridge 2000). The feasibility of the use of plasmid DNA vaccines in humans is not yet known and it will likely take at least 15 years before this approach is sufficiently studied and - more importantly - accepted, particularly for neonates. Candidate vaccines based on vector delivery systems are constructed of live recombinant vectors expressing RSV proteins. For example, recombinant vaccinia virus expressing RSV-F and G provided protection in mice, but lacked this effect in chimpanzees (Collins 1990). The question is whether these systems are safe (notably vaccinia virus) and feasible in the light of existing (maternal) antibodies against poxviruses in the community and the main target group being neonates.

Several vaccine candidates are based on recombinant live RSV, generated by reverse genetics. One line of study focuses on attenuating these viruses by introducing the individual or combined mutations responsible for cold-adaptation and temperature-sensitivity into the recombinant virus. None of these vaccine candidates were usable, because of either over- or underattenuation. Another line of study focuses on deletion of one or more viral non-structural genes. Limited data are available on the behaviour of these viruses in model systems (Jin 2003).

An alternative approach to RSV vaccine development is the use of bovine RSV. A chimeric bovine RSV with either the human F protein alone or both the human F and G protein was evaluated for its efficacy in chimpanzees. This vaccine candidate was restricted in replication to such a degree that animals were not protected after wild type h-RSV challenge (Buchholtz 2000).

Thus, currently there is no effective h-RSV vaccine available in the art. All RSV vaccine candidates that have been tested in animal models are unusable in humans. There is thus a long felt need in the art for RSV vaccines that are both effective and safe and it is an object of the present invention to provide for such vaccines.

Summary of the Invention

In a first aspect, there is provided a virion of a pneumovirus comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion.

In a second aspect, there is provided a method for producing pneumoviral virions, the virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for (in vivo) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion, the method comprising the steps of:

- (a) infecting a culture of a first host cell with a pneumovirus comprising a viral genome that has the mutation, whereby the host cell comprises an expression vector which directs expression in the host cell of the protein in a form and in an amount that is required for infectivity of the virion; and,
- (b) recovery of the virions from the infected host cell culture.

In a third aspect, there is provided a composition comprising a virion as defined above, or obtainable in a method as defined above, and a pharmaceutically acceptable carrier.

In the fourth aspect, there is provided use of a virion as defined above for the manufacture of a medicament for the prevention or treatment of a pneumoviral infection.

Description of the Invention

Definitions

In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one

of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".

The term "virion" as used herein refers to a virus particle that contains the nucleocapsid protein, the viral genome and the replicase complex in a lipid envelop that
5 contains the viral structural glycoproteins.

The terms "infectivity of a virus", "infectious virus", "infectious virus particle" or "infectious virion" denote viruses, virus particles or virions that are capable of entering suitable host cells and initiating a virus replication cycle, whether or not this leads to the production new virus that is infectious.

10

Detailed description of the invention

In a first aspect the present invention relates to a virion of a pneumovirus. The virion comprises a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus
15 produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion.

The pneumovirus preferably is a Respiratory Syncytial Virus (RSV), more preferably a human or bovine RSV. The human RSV may either be a subgroup A or B
20 virus, and preferably is a clinical isolate, more preferably an isolate that has not been extensively passaged *in vitro* (preferably passaged less than 10, 8, 6 or 5 times as described in the Examples). Therefore, any RSV strain or isolate may be used in the context of the present invention, whereby is understood that the invention is only exemplified by means of the particular human RSV isolate 98-25147-X, referred to as
25 RSV isolate X. Further preferred is that virus is a recent clinical isolate whereby recent is defined as being first isolated less than 10, 8, 6, 4, 3, or 2 years ago. It will be understood that although the nucleotide sequences in the virion do not need to correspond to those of the recent isolate, preferably, the amino acid sequences of the proteins present in the virion of the invention are identical to the proteins as they occur
30 in a recent clinical isolate.

The viral genome comprises at least one mutation in at least one viral gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the infectivity of the virus is as defined above. Thus, the protein that is essential for

infectivity of the pneumovirus is a protein that is essential for the capability of the virion of the invention to enter a suitable host cell and initiate a viral replication cycle, whereby the replication cycle does not necessarily lead to the production of new infectious virions. In preferred virions of the invention the mutation causes the virion to lack infectivity *in vivo*, i.e. in a suitable host organism, whereby the virions may still be infectious for suitable host cells cultured *in vitro*.

In a preferred virion of the invention, the mutated gene that codes for a protein essential for infectivity of the pneumovirus, is a gene, which codes for a structural protein of the virus. A structural protein of a pneumovirus is herein understood to be a protein that is present in virions of wild-type infectious virus. Preferred genes coding for structural proteins to be mutated in the virions of the invention are the genes coding for the attachment protein G and/or the fusion protein F, whereby the G protein is most preferred. Deletion and/or functional inactivation the gene coding for G protein serves several purposes and prevents a number of problems and complications of current RSV vaccine candidates. One purpose is vaccine safety: RSV without G protein is highly attenuated in its host (Karron 1997, Schmidt 2002) because it will not be able to efficiently infect host cells. One complication is that the G protein is strongly implicated in causing undesired immunological responses, including enhanced immune pathology (Alwan 1993, Srikiatkachorn 1997b) and possible skewing of the immune system towards an allergy (and asthma-) prone state under certain genetic predispositions (Openshaw 2003, Peebles 2003). This will be prevented by deletion or inactivation of the G gene. A pneumoviral virion of the invention comprising a viral genome that has an inactivating mutation in the gene coding for a G attachment protein, and comprising the G attachment protein in a form and in an amount that is required for infectivity of the virion is referred to as a " Δ G+G" (pneumo)virus or virion. Similarly, the virion that has the inactivating mutation in the gene coding for a G attachment protein, but which is not complemented *in trans* with a functional amount of G protein is referred to as a " Δ G" (pneumo)virus or virion.

The pneumoviral virions of the invention are thus transiently and functionally reconstituted with an externally encoded protein that is essential for infection. Preferably the externally encoded protein that is essential for infection is the attachment protein G and/or the fusion protein F, whereby the G protein is most preferred. Preferably the externally encoded protein that is essential for infection is of the same

viral subgroup (A or B) as the genome that is present in the virion. More preferably the externally encoded protein that is essential for infection is homologous to the genome that is present in the virion, whereby is meant that the protein has the same amino acid sequence as the amino acid sequence that was encoded in the genome of the virus prior to its inactivation. Alternatively, this may mean that the externally encoded protein has the same amino acid sequence as present in a wild type virion of which the amino acid sequences with one or more internally encodes proteins have 100% identity with their counter part in the virion of the invention.

In the virions of the invention, the mutation in the gene of the essential structural protein is a mutation that causes the virus produced from only the viral genome to lack the protein or to express a biologically inactivated protein. Production of virus from only the viral genome is understood to mean virus produced exclusively from the viral genome as present in the virions and in the absence of any coding sequence complementing the viral genome *in trans*. The viral genome as present in the virions is thus incapable of directing expression of the essential structural protein. This may be achieved in various ways known to the skilled person, including e.g. inactivation of the translation initiation codon, introduction of stop codons near the N-terminus of the encoded protein, one or more frame-shift mutations, deletion of one or more fragments from the gene. Preferably the gene is inactivated by deletion of at least 10, 20, 50, 75, 90 or 95% of the sequence coding for the essential structural protein. Most preferred is however, a virion in which the mutation comprises deletion of the (entire) sequence coding for the protein.

Explicitly included in the invention are virions in which more than one mutation is present. In particular, more than one viral protein-coding gene may comprise mutations that inactivate or alter the function of the protein in question, or which cause the protein to lack from the virions as described above. E.g. the cold-passaged or heat-sensitive mutations as known in the art may be combined with inactivation of the essential structural proteins as disclosed in the invention above.

Clearing of pneumoviruses like RSV from the infected host organisms requires proper cellular immunity, which will not be effectively mounted without infection of epithelial cells by the virus. However, the mutant pneumoviruses of the invention lack genetic information for a protein that is essential for infection of host cells *in vivo*. Therefore the present invention discloses methods for the production of the mutant

pneumoviruses, which include replication of mutant pneumoviruses in cells that complement (*in trans*) for the absence of the protein that is essential for infection.

In another aspect the invention thus pertains to a method for producing the above defined mutant pneumoviral virions. The method is a method for producing
5 pneumoviral virions, whereby the virions comprise a viral genome that has a mutation in a gene coding for a protein that is essential for (*in vivo*) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The method comprises the
10 steps of: (a) infecting a culture of a first host cell with a pneumovirus comprising a viral genome that has a mutation as defined above, whereby the host cell comprises an expression vector which directs expression, either transiently or constitutively, in the host cell of the protein in a form and in an amount that is required for infectivity of the virion; and, (b) recovery of the virions from the infected host cell culture. Recovery of
15 virions from the infected host cell culture may include either or both recovery from the culture medium as well as recovery from the cells.

The first host cell may be any host cell in which the pneumovirus is capable of replication, with or without the simultaneous expression *in trans* of the protein that is required for infectivity of the virion. Suitable host cells for this purpose are e.g. African
20 green monkey kidney cell cultures (such as e.g. Vero, ECACC lot 10-87, 134th passage, 1990, EMEA approved).

In a preferred method of the invention, the pneumovirus that is used to infect the culture of a first host cell culture, is produced in a method comprising the steps of: (a) providing to a second host cell one or more expression vectors which direct expression
25 in the host cell of: (i) a viral genomic RNA that has a mutation in a gene coding for a protein that is essential for (*in vivo*) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity; and, (ii) a pneumoviral polymerase enzyme complex and optionally one or more further viral proteins; and, (b) culturing the second host cell whereby the virions are produced.
30 In a preferred method, the virions produced by the second host cell are amplified by one or more further cellular infection steps employing host cells which are the same or different from the second host cell.

The second host cell may be any host cell in which the pneumovirus is capable of replication, with or without the simultaneous expression *in trans* of the protein that is required for infectivity of the virion. Suitable host cells for this purpose are e.g. African green monkey kidney cell cultures (such as e.g. Vero, ECACC lot 10-87, 134th passage, 5 1990, EMEA approved), or Hep-2 cells. The second host cell may be the same as or different from the first host cell.

In the methods of the invention, the viral genomic RNA is transcribed from a viral DNA copy that is under the control of a bacteriophage DNA-dependent RNA polymerase promoter and whereby the (second) host cell is provided with an expression 10 vector which directs expression in the host cell of the bacteriophage DNA-dependent RNA polymerase. Preferably, the bacteriophage DNA-dependent RNA polymerase is a T7, T3 or SP6 polymerase.

The pneumoviral polymerase enzyme complex that is expressed from one or more expression vector(s) in the second host cell at least includes the L, P, N proteins 15 expressed from their corresponding genes or cDNA's in the expression vector(s). For improved efficiency of viral assembly and packaging of the naked viral genomic RNA, optionally, one or more further viral proteins are expressed in the second host cells. Preferred viral proteins for this purpose include the viral matrix membrane proteins of which the M2-1 protein is particularly preferred. The L, P, N, M2-1, G or F proteins are 20 preferably derived from the viral genome of the viral isolate which is introduced and expressed in the host cell, but alternatively also homologous proteins from other heterologous viral or non viral sources may be used.

The skilled person will appreciate that a wide variety of expression vectors and regulatory sequences (such as promoters) are available in the art for expression of the 25 viral genomic RNA, the DNA-dependent RNA polymerase, pneumoviral polymerase enzyme complex and optional further viral proteins, as well as the essential structural protein, in the first and/or second host cells (see e.g. Sambrook and Russell (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York).

30 For reverse genetics of RNA viruses, i.e. expression of a recombinant RNA virus such as the virions of the present invention, a cDNA copy of the viral genomic RNA is cloned into plasmids and is placed under the control of sequences that will allow synthesis of RNA from the DNA under certain conditions. Generally, the promoter

sequence for bacteriophage RNA polymerase (e.g. the T7 RNA polymerase) is placed upstream of the DNA copy of the RNA genome, while an appropriate terminator for the RNA polymerase is placed downstream of the genome. Self-cleaving ribozyme sequences are placed upstream of the terminator sequences, to allow synthesis of RNA
5 with the correct terminal nucleotides. Correct terminal sequences are generally required to rescue virus from the synthetic RNA. For non-segmented negative strand RNA viruses, co-expression of the polymerase enzyme complex (N, P and L proteins for Paramyxoviruses) along with the genomic or anti-genomic RNA is required to obtain recombinant virus (reviewed by Neumann 2002 and exemplified in the Examples
10 herein).

Other preferred methods may comprise the further step of isolating and/or purifying the virions of the invention and/or formulating these virions into pharmaceutical compositions. Methods for isolating and/or purifying virions are well known to the skilled virologist. Such methods e.g. include various centrifugation
15 techniques (e.g. differential or density centrifugation), or chromatographic techniques. A method for formulating the virions of the invention into a pharmaceutical composition at least comprises the step of mixing the virions with a pharmaceutically acceptable carrier as defined below.

In a further aspect the invention relates to a composition comprising a virion as
20 defined above or obtainable in a method as defined above, and a pharmaceutically acceptable carrier. The composition preferably is a pharmaceutical composition that is preferably suitable for use as a vaccine, i.e. the composition preferably is a vaccine.

In a yet another aspect the invention provides for a pharmaceutical preparation comprising as active ingredient a virion according to the invention, and a
25 pharmaceutically acceptable carrier. Pharmaceutically acceptable stabilising agents, osmotic agents, buffering agents, dispersing agents, and the like may also be incorporated into the pharmaceutical compositions. The preferred form depends on the intended mode of administration and therapeutic application. The pharmaceutical carrier can be any compatible, non-toxic substance suitable to deliver the reconstituted
30 viral membranes to the patient. Pharmaceutically acceptable carriers for intranasal delivery are exemplified by water, buffered saline solutions, glycerin, polysorbate 20, cremophor EL, and an aqueous mixture of caprylic/capric glyceride, and may be buffered to provide a neutral pH environment.

For administration by inhalation, the pharmaceutical compositions of the present invention are conveniently delivered in the form of an aerosol spray from pressurised packs or a nebuliser, wherein the virions are present in a carrier as described for intranasal delivery but with the use of a suitable propellant, e.g.,

- 5 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

Methods for preparing intranasal or inhalant compositions are well known in the art and described in more detail in various sources, including, for example,

- 10 Remington's Pharmaceutical Science (15th ed., Mack Publishing, Easton, PA, 1980) (incorporated by reference in its entirety for all purposes). The virions may thus be formulated as the active component in any preparation for vaccination, which may further e.g. include carriers, adjuvants, stabilisers, solubilisers, preservatives and other excipients known in the art, to allow or to aid efficient administration of the preparation
15 for vaccination to individuals, preferably human and live stock or farm animals (such as cows, pigs, horses, goats, sheep).

In a further aspect, the invention relates to a method for vaccination against, or for prophylaxis or therapy (prevention or treatment) of an pneumoviral infection by administration of a therapeutically or prophylactically effective amount of (a
20 pharmaceutical composition comprising) the virions of the invention as defined above, or obtainable as defined above, to a subject in need of prophylaxis or therapy. Preferably, the virions are administered intranasally.

- The invention similarly relates to virions of the invention as defined above, or obtainable as defined above, for use as a medicament, preferably a medicament for
25 vaccination against, or for prophylaxis or therapy of a pneumoviral infection. The invention further relates to the use of the virions of the invention in the manufacture of a medicament for vaccination against, or for prophylaxis or therapy of a pneumoviral disease or infection. Preferably the medicament is a preparation for intranasal administration.

- 30 The compositions comprising the virions of the invention for vaccination are preferably administered intranasally to appropriate hosts. In one embodiment, calves are to be protected from b-RSV infections. In yet another embodiment, humans, of which preferably infants and elderly or immune compromised individuals are protected

from h-RSV infections. Formulations preferably comprise formulations suitable for administration as intranasal drops or spray, preferably a nasal spray. The $\Delta G+G$ -pneumoviral particles in the composition will infect epithelial cells of the upper respiratory tract only once because the second generation virions produced from the initially infected URT epithelial cells lack the G attachment protein for which the coding sequence has been removed from the genome. These ΔG -virions are therefore non-infectious *in vivo* in host organisms. However, the initial single cycle of infection allows for the development of appropriate cellular immunity - that is a response capable of clearing wild-type virus infection - to be mounted against pneumovirus, or RSV in particular, while protective antibodies against F - i.e. antibodies that will prevent lower respiratory tract infection - will be elicited by the vaccine and the non-infectious progeny. Anti-F antibodies are effective in limiting RSV infection, as is shown by the effectiveness of Palivimuzab treatment, which is a humanised monoclonal antibody against F. This is the basis of the efficacy of the recombinant live attenuated pneumoviral vaccines of the invention. These live viral vaccines solves a number of problems associated with current pneumovirus vaccine candidates. The presence of the G-protein in its natural context in the virion allows for the development of appropriate cellular immunity whereas the undesirable effects of immunity against the isolated G protein that is largely responsible for immune enhancement of b-RSV and h-RSV pathology in cattle and humans respectively, is avoided.

Description of the figures

Figure 1: Diagram of construction of pRSVX ΔG . Upper line represents RSV isolate X genomic RNA, with genes indicated. Boxes below represent RT-PCR products and oligonucleotide duplexes used for construction. Numbers inside boxes indicate the oligonucleotide numbers as listed in table I. Restriction sites introduced for cloning are indicated. The final cloning scheme is indicated below: circles are plasmids and the arrows show the order of cloning.

Figure 2. Alignments showing the differences between RSV isolate X and pRSVX ΔG sequences. Sequences are shown as alignment of genomic sense. For pRSVX ΔG only nucleotides differing from RSV isolate X are indicated. Similar sequences are indicated by dots (.) and gaps are indicated by (-). Gene start signals are single underlined, gene stop signals double underlined, and the genes are indicated in the captions. Boxes

outline the restriction enzyme recognition sites resulting from the nucleotide changes introduced.

Figure 3. Identification of sequence markers in RSV RT-PCR amplification products, digestions digests: a) MluI, b) XmaI, c) SexA-I, d) SnaB-I.

5 Figure 4. Growth curves of RSV isolate X and ΔG-RSV isolate X. Vero (solid lines) and Hep-2 (dashed lines) cells were infected with virus at MOI=0.1 and incubated at 37°C. At the indicated time points cells were harvested and CCID50 titres were determined on Vero cells.

Table I. Primers used for RT-PCR cloning of RSV isolate X.

10 Table II. Primers used for cloning of helper plasmids and for plasmids used for construction of stable cell lines.

Table III. Primers used for diagnostic RT-PCR on RNA from RSV infected Vero cells.

Table IV. Results cotton rat immunization experiments, protection against RSV infection and RSV-induced pathology by ΔG-RSV isolate X immunization.

15

Examples

The current invention is illustrated by the following non limiting examples that are merely used to illustrate specific embodiments of the invention and should not be read as limiting the general scope or any aspect of the invention.

20

Example 1

Viral isolate, virus isolation, propagation and storage

The basis for the recombinant h-RSV clone is a clinical RSV isolate, obtained from the Leiden University Medical Centre diagnostic laboratory. This virus, named
 25 98-25147-X, coded after the patient from which it was isolated, was derived from a diagnostic test on Hep-2 cells in the period 21-24 December 1998. It was later determined to be a subtype A isolate and is designated RSV isolate X. The virus was passaged 4 times on Hep-2 cells in T75 bottles in DMEM (Gibco), 10% FCS, pen/strep/glu and subsequently five times on Vero cells in T75 bottles on in DMEM
 30 (Gibco), 10% FCS, pen/strep/glu. The resulting RSV isolate X virus was used as working stock and stored at -135°C in 25% or 45% sucrose.

Example 2

Construction of RSV-X cDNA encoding viral genome

Total RNA was obtained by phenol-guanidine isothiocyanate extraction (Trizol, Invitrogen) of stock RSV isolate X infected Vero cells. cDNA was prepared by reverse transcription using Thermoscript (Invitrogen) reverse transcriptase using random
 5 hexamer primers. This cDNA was used as template for PCR using High fidelity Taq polymerase (Invitrogen) using specific primers containing restriction enzyme recognition sites (Table I and sequence listing). Primers were designed based on the published sequences of RSV-A2 (Genbank accession no M74568) and RSV-RSS2 (Genbank accession no U39662).

- 10 PCR products were first cloned individually in different vectors: primer pairs, vectors, restriction enzyme recognition sites and resulting vector name are listed below.
 RSV021/RSV047: pCAP vector (Roche), bluntly into Mlu N1, pCAP3 (SH/M/P region)
 RSV018/019: pCAP vector, bluntly into Mlu N1, pCAP2 (G region)
 15 RSV016/RSV017: PUC21, Mlu I/Bam HI, pUK5 (M2-2/M2-1/F region)
 RSV024/RSV025a : PUC21, Bam HI/Afl II, pUK1 (NS2/NS1 region)
 RSV022/ RSV023: PUC21, EcoR V, pUK4 (N region)
 RSV014/ RSV015: PUC21, Kpn I/Mlu I, pUK2 (L region)

- At least two individual clones derived from two independent cDNA templates
 20 were sequenced; regions containing differences between the two clones were sequenced on a third clone. If necessary, clones were repaired using standard molecular biology techniques known by the skilled person. Additional PCR products covering the binding sites of the primers used for cloning were obtained and sequenced. The 5' genomic termini were determined by poly-adenylation of genomic RNA, followed by
 25 RT-PCR with an oligo(d)T containing primer ALG018:

TTAAAAGCTTTTTTTTTTTTTTTTTTTT

and an NS1 gene primer RSV126:

AATTCTGCAGGCCCATCTCTAACCAAAGGAGT.

- This fragment was cloned into pUC21 using Hind III/Pst I. The 3'-end was determined
 30 by RACE (rapid amplification of cDNA ends) ligation PCR. All sequences were assembled to yield the RSV-X consensus sequence (Seq ID No. 1).

All sequences were confirmed by PCR cycle sequencing using the BigDye terminator kit (Applied Biosystems) and analysed by an ABI Prism 310 genetic analyser.

5

Example 3

Construction of ΔG-RSV isolate X full length plasmid

The full-length cDNA spanning the entire RSV isolate X genome was assembled by sequential ligation of PCR fragments (Figure 1). The "trailer" end is preceded by the promoter for the bacteriophage T7 polymerase. To generate correct 3' ends the cDNA
10 "leader" end is fused to the hepatitis delta virus ribozyme (HDVR), followed by a terminator of the T7 RNA polymerase transcription (see Figure 1).

First, two sets of complementary oligomers encoding the HDVR and the T7 terminator RSV026/RSV027 oligo's and RSV028/029 oligo's were phosphorylated with T4 DNA kinase, hybridised and ligated into clone pUK1 (containing genes
15 NS1/NS2) via Rsr II /Not I, giving plasmid pUK3. Then, the Xma I/SexA I fragment of clone pUK4 containing N was ligated into plasmid pUK3 via Xma I/SexA I. This plasmid (pUK6) contains the region from the N gene up to the 3' leader sequence, fused to the HDVR and a T7 terminator.

Secondly, the Xma I/Eco RV fragment of plasmid pCAP3 was inserted in
20 plasmid pUK5 using Xma I and a filled-in Hind III site. This yields plasmid pUK8. Subsequently, pUK 8 was digested with BssH II and BsiW I, ends were filled-in with Klenow polymerase and religated. This plasmid contains the genes M2-2, M2-1, F, SH, M and P and is named pUK9.

To synthesise a low-copy number vector for the RSV isolate X cDNA, two
25 complementary oligomers, RSV011:
AGCTTGCGGCCGCGTCGACCCGGGACGCGTCGATCGGGTACCAT and
RSV012: CGATGGTACCCGATCGACGCGTCCCGGGTTCGACGCGGCCGCA were
phosphorylated with T4 DNA kinase, hybridised and inserted in the alkaline
phosphatase treated and Cla I /Hind III digested plasmid pACYC184 (New England
30 Biolabs). The resulting plasmid is named pACYC184-MCS. Subsequently a Mlu I-
Knp I fragment of pUK2 containing the T7 promoter and L gene was inserted, this
intermediate plasmid is named pACYC1. Then, the region from the N gene up to the
3'-leader sequence, including the fused HDVR and T7 terminator sequence of pUK6

was added to pACYC1 using Xma I/Not I. This gives intermediate plasmid pACYC2. Finally, the Xma I/Mlu I fragment of pUK9 containing the M2-2, M2-1, F, SH, M and P genes was inserted into pACYC2, yielding plasmid pACYC3, comprising the whole RSV genome of strain X lacking the G gene. Sequence analysis of the latter plasmid revealed a deletion in the HDVR region, which was repaired and the resulting plasmid is named pRSVXΔG.

In addition to construct pRSVXΔG, construct pACYC24 was generated in which the genomic RSV isolate X insert is reverse complemented via inverse PCR. From the construct, antigenomic RSV RNA can be synthesised. In pACYC24, the T7 promoter precedes the 3'-leader sequence, whereas the HDVR and T7 terminator are fused to the 5'-trailer sequence.

All restriction enzyme recognition sites used to construct pRSVXΔG are located inside the RSV intergenic regions and do not alter coding sequences or affect transcription signals (as shown in Figure 2).

Example 4

Construction of helper plasmids

Helper plasmids expressing several RSV proteins were constructed as follows. All required genes are derived from lab-strain RSV-A2 (ATCC #VR1302). Virus was plaque-purified on Hep-2 cells and subsequently used to infect Vero cells. Total RNA was isolated from these cells by phenol-guanidine isothiocyanate extraction (Trizol, Invitrogen) and subjected to RT-PCR using High Fidelity Taq polymerase (Invitrogen) and a set of primers specific for RSV genes L, P, N and M2-1 respectively (see Table II). PCR products were subsequently cloned into expression plasmids pcDNA3, pcDNA6 or pCI, using restriction enzyme recognition sites as indicated in the table II. Clone sequences were confirmed by PCR cycle sequencing using the BigDye terminator kit (Applied Biosystems) and analysed by an ABI Prism 310 genetic analyser.

Example 5

Construction of G-producing Vero cell-lines

Cell lines producing RSV-G protein were constructed using several methods:

In method 1, the G gene from either RSV-A2 or RSV isolate X, or the G gene from RSV-A2, in which the internal translation initiation codon had been disabled by modification using primers RSV033 and RSV 034, were cloned into expression vector pcDNA3 or pcDNA6 (Invitrogen) using RT-PCR on RNA from RSV-A2 or RSV isolate X infected Vero cells using primers as indicated in Table II. The plasmids were introduced into Vero cells using either chemical agents CaCl_2 co-precipitation, liposome-based or electroporation (Ausubel 1989). Two methods for isolating stable cell lines were used. In the first method, 72 hours after transfection, cells were split using various dilutions into fresh medium containing selective medium, zeocin for pcDNA3 and blasticidin for pcDNA6. Cells were fed with selective medium every 3-4 days until cell foci were identified. Single colonies were picked and transferred in to 96-well plate, or seeded in various dilutions to obtain single cells in a 96 well plate. Antibiotic resistant colonies were tested on expression of RSV-G by immunostaining techniques or FACS using RSV G-specific antibodies. Colonies expressing G were passaged, and were designated as stable cell lines expressing G. The second method comprises FACS sorting using RSV-G specific antibodies 72 hours after transfection. RSV-G expressing cells were seeded in a serial dilution to obtain single cells in a 96-well plate and cultured with selective medium. Single cell colonies were passaged on selective medium and subsequently tested again for expression of RSV-G, resulting in cell lines expressing RSV-G.

In method 2, the Flp-In system (Invitrogen) is used to produce Vero cells with target gene insertion sites at chromosomal positions which allow different levels of target gene expression. The RSV-G gene, derived from the plasmids from method 1 but with a modification (introduced using primer RSV151: Table II) of the G translation initiation codon surrounding sequence to allow higher translation levels, were inserted in each of these cell lines using the system-generic method, resulting in Vero cell lines stably expressing different levels of G protein.

In method 3, Vero cells were transiently made to express the G protein, by either transfection with the expression plasmids containing the G gene from method 1, or by infection with Modified vaccinia virus Ankara (MVA) (Sutter 1992) or fowlpox viruses (Spehner 1990) expressing the G protein.

Example 6

Construction of bacteriophage T7-polymerase-producing cell lines

The bacteriophage T7 polymerase gene is PCR amplified from plasmid pPRT7 (van Gennip 1997), containing the gene, using primers ALG022 and ALG023 (Table II). The PCR product is cloned into pcDNA6b vector, using Hind III/Xba I, yielding
5 plasmid pc6T7pol. Vero cells were transfected using lipofectamine 2000 as recommended by the manufacturer (Invitrogen). 72 hours after transfection cells were split and grown in fresh medium containing blasticidin. Cells were fed fresh medium every 3-4 days and split twice to obtain larger culture volumes. 20 days after transfection, blasticidin resistant cells were transfected with reporter plasmid pT7-
10 IRES2-EGFP using lipofectamine 2000. For the construction of plasmid pT7-IRES2-EGFP, first plasmid pT7-EGFP was constructed by inserting via HindIII/BamHI in plasmid p-EGFP-N1 (Clontech) a set of complementary oligomers encoding for the T7 promoter sequence (ALG32: AGCTAATACGACTCACTATAGGGAGACGCGT and ALG33: GATCACGCGTCTCCCTATAGTGAGTCGTATT). Plasmid pT7-
15 IRES2-EGFP was then constructed by cloning the T7-EGFP fragment of plasmid pT7-EGFP into plasmid p-IRES2-EGFP via XmaI-NotI. Cells expressing EGFP were sorted by FACS and grown in limited dilution to obtain single cell colonies. Single colonies expressing T7 RNA polymerase were tested for stability, grown to larger culture volumes and stored.

20

Example 7Method to produce recombinant Δ G-RSV isolate X virus

Hep-2 cells were cultivated in DMEM + 10% FCS (foetal calf serum) + penicillin/ streptomycin/ glutamine, whereas Vero cells and derivatives thereof are
25 cultivated in M199 + 5% FCS + pen/strep/glu. Cells were grown overnight to 80% confluence in 10 mm² dishes at 37°C. For Vero and Hep-2 cells, cells were infected with modified virus Ankara-T7 (MVA-T7)(Sutter 1992, Wyatt 1995) or fowlpox-T7 virus (Britton 1996) at MOI = 3 (multiplicity of infection 3) and incubated at 32°C for 60 min prior to transfection, to allow expression of bacteriophage T7 polymerase. The
30 cells (Hep-2, Vero or Vero-T7 cells) were washed with Optimem medium (Optimem 1 with glutamax, Invitrogen) and subsequently transfected with helper plasmids encoding the N, P, L and M2.1 genes of RSV and with plasmid pRSVX Δ G, using Lipofectamine2000 (Invitrogen) in Optimem (total volume 500 μ l). The following

amounts of plasmids were added: 1.6 μ g pRSVX Δ G, 1.6 μ g pcDNA6-A2-N, 1.2 μ g pcDNA3-P, 0.4 μ g pcDNA6-A2-L, 0.8 μ g pcDNA6-A2-M2.1. After 3-4 hrs of incubation at 32°C, 500 μ l of Optimem medium with 2% FCS was added and the cells were incubated at 32°C for 3 days. Cells were then scraped and the mixture of scraped
5 cells and medium containing the rescued virus was used to infect fresh cultures of Vero or Hep-2 cells grown in DMEM + 2% FCS + pen/strep/glu. The latter procedure was repeated for 4-5 times to obtain high titre virus stocks.

Identity of Δ G-RSV isolate X virus was confirmed by RT-PCR on RNA isolated from Δ G-RSV isolate X infected Vero cells and digestion of the obtained products with
10 the unique restriction enzymes whose recognition sites were introduced into pRSVX Δ G (figure 2). RSV isolate X was used as control.

For the identification of sequence markers in RSV, Vero cells were infected with RSV isolate X or with Δ G-RSV isolate X with an MOI= 0.1. 72 hrs after infection, RNA from culture supernatants was isolated and used as template for RT-PCR.
15 Primers were designed to flank the inserted sequence markers in the recombinant Δ G-RSV isolate X virus. After RT-PCR, the obtained products were digested with the appropriate restriction enzymes. The following digestion products were obtained (figure 3):

a) PCR with primer RSV065 (GTCCATTGTTGGATTTAATC) and RSV093
20 (CAAGATAAGAGTGTACAATACTGTC) and digestion with Mlu-I yielded the expected fragments of 937 bp for RSV isolate X, and 459 and 478 bp for Δ G-RSV isolate X

b) PCR with primers RSV105 (GTTGGATTGAGAGACACTT) and RSV113 (AGTATTAGGCAATGCTGC) followed by digestion with Xma-I yielded the
25 expected fragments of 880 bp for RSV isolate X, and 656 and 224 bp for Δ G-RSV isolate X

c) PCR with primers RSV112 (CCCAGTGAATTTATGATTAG) and RSV160 (AATTGGATCCATGGACACAACCCACAATGA) and digestion with SexA-I yielded the expected fragments of 694 bp for RSV isolate X, and 492 and 202 bp for
30 Δ G-RSV isolate X

d) PCR with primers RSV098 (TGGTAGTTCTCTTCTGGCTCG) and RSV114 (ATCCCCAAGTCATTGTTCA) followed by digestion with SnaB-I yielded the

expected fragments of 1820 bp for RSV isolate X, and 507 and 387 bp for Δ G-RSV isolate X.

Growth characteristics of Δ G-RSV isolate X compared to RSV isolate X were determined on Vero and on Hep-2 cells (figure 4).

5

Table III. Primers used for diagnostic RT-PCR on RNA from RSV infected Vero cells.

<i>Primer name</i>	<i>Sequence</i>
RSV065	GTCCATTGTTGGATTTAATC
RSV093	CAAGATAAGAGTGTACAATACTGTC
RSV098	TGGTAGTTCCTCTTCTGGCTCG
RSV105	GTTGGATTGAGAGACACTT
RSV112	CCCAGTGAATTTATGATTAG
RSV113	AGTATTAGGCAATGCTGC
RSV114	ATCCCCAAGTCATTGTTCA
RSV160	AATTGGATCCATGGACACAACCCACAATGA

Example 8

10

Method to produce recombinant Δ G+G-RSV isolate X virus

Δ G-RSV isolate X virus, derived from transfected Vero cells, was passaged several times to obtain titres of at least 10^5 pfu/ml (plaque forming units per ml).

Different moi's of this virus were then used to infect the Vero cell line producing RSV-G protein. The resulting Δ G+G-RSV isolate X was harvested from the medium and/or
 15 from the cells and analysed for the presence of the G protein in the virions by immunodetection techniques. Infectivity titres were determined on Vero or Hep-2 cells, and the integrity of the Δ G-genome was determined using RT-PCR on viral RNA extracted from cells infected with Δ G+G-RSV isolate X virus. Virus was stored at -135^0 C in 25% or 40% sucrose.

20

Example 9

Method to protect in a cotton rat animal model against RSV infection and RSV-induced pathology by Δ G-RSV isolate X immunization

Protection experiments were performed in cotton rats (*Sigmodon hispidus*, 5-6 weeks old, 4-6 animals per group and both sexes). In initial experiments, this animal was shown to be sensitive to RSV infection and to exhibit severe vaccine-mediated lung pathology as described by Prince, 2001 and which closely mimics the human situation. After intranasal application of RSV lung pathology was characterized by inflammation infiltrate in and around bronchus/bronchioli and hyperplasia of epithelium. A more severe pathology was seen upon intramuscular immunization with formalin-inactivated RSV-A2 followed by an intranasal challenge with RSV-A2. In addition to the above-mentioned pathology, perivascular and peribronchiolar infiltrate and alveolitis were observed, characteristic for an immune-mediated pathology. These observations were used as "internal" reference for all immunization and challenge experiments.

Infection and immunization of cotton rats with RSV preparations was done intranasally, in both nostrils. Cotton rat lungs were examined for pathology lightmicroscopically and virus titres at different time points post-challenge or post-infection/immunization were determined on Vero cells using serial dilutions of lung homogenates with RSV specific ELISA to yield CCID₅₀ titres and immunostaining using RSV specific abs to yield pfu titres. After immunization twice with ΔG-RSV isolate X cotton rats were fully protected against infection and pathology caused by RSV isolate X in the lungs. The results from several experiments are summarized in Table IV.

Table IV:

		<i>infection with:</i>		t^1	V^2	<i>lung pathology day 5</i>	<i>lung t^3</i>
						<i>post infection</i>	
		ΔG-RSV	isolate X	5	100	yes, moderate	below detection
		RSV-A2		5	100	yes, strong	2*5
		RSV isolate X		5	100	yes, strong	4*5
<i>immunization</i>	t^1	V^2	<i>challenge day</i>	t^1	V^2	<i>lung pathology day 5</i>	<i>lung t^3</i>
<i>day 0 and 21</i>			42			<i>post challenge</i>	
2x ΔG-RSV	5	100	RSV isolate X	5	100	no	below

isolate X						detection
mock	100	RSV isolate X	5	100	yes, strong	5

¹: virus titres in logs pfu/ml

²: volume in μ l per animal, which is half this volume in each nostril

³: virus titres in logs per gram lung, detection limit is 10^2 CCID₅₀

5

References

- Alwan WH, Record FM, Openshaw PJ. Phenotypic and functional characterisation of T cell lines specific for individual respiratory syncytial virus proteins. *J Immunol.* 1993, 150(12):5211-8.
- 10 F.M. Ausubel, R. Brent, R. E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl, *Current Protocols in Molecular Biology*, John Wiley and Sons, New York, 1997
- Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. *J Gen Virol.* 2000, 81(Pt 15 10):2519-23.
- Britton P, Green P, Kottier S, Mawditt KL, Penzes Z, Cavanagh D, Skinner MA. Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. *J Gen Virol.* 1996, 77 (Pt 5):963-7.
- 20 Buchholz UJ, Granzow H, Schuldt K, Whitehead SS, Murphy BR, Collins PL. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. *J Virol.* 2000, 74(3):1187-99.
- Cane PA, Matthews DA, Pringle CR. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. *J Gen Virol.* 1991, 25 72 (Pt 9):2091-6.
- Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. *Vaccine.* 1990, 8(2):164-8
- 30 Crowe JE Jr. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. *Vaccine.* 1998, 16(14-15):1423-32. Review.

- Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PPF-2) in healthy young and older adults. *Vaccine*. 2000, 18(17):1763-72.
- 5 Greenough A, Thomas M. Respiratory syncytial virus prevention: past and present strategies. *Expert Opin Pharmacother*. 2000, 1(6):1195-201.
- Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. *Vaccine*. 2003, 21(25-26):3647-52.
- 10 Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterisation of a cold-passaged, attenuated RSV subgroup B mutant. *Proc Natl Acad Sci U S A*. 1997, 94(25):13961-6.
- 15 Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. *Am J Epidemiol*. 1969, 89(4):422-34.
- Li X, Sambhara S, Li CX, Ewasyszyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M. Protection against respiratory syncytial virus infection by DNA immunization. *J Exp Med*. 1998, 188(4):681-8.
- 20 Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. *Clin Ther*. 2000, 22(11):1357-69.
- 25 Mufson MA, Belshe RB, Orvell C, Norrby E. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. *J Infect Dis*. 1988, 157(1):143-8.
- Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? *J Gen Virol*. 2002, 83(Pt 11):2635-62. Review.
- 30 Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. *Pediatr Infect Dis J*. 2003, 22(2 Suppl):S58-64; discussion S64-5. Review.

Peebles RS Jr, Hashimoto K, Graham BS. The complex relationship between respiratory syncytial virus and allergy in lung disease. *Viral Immunol.* 2003;16(1):25-34. Review.

- Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaia N, Nguyen TN,
5 Power UF. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. *Vaccine.* 2003, 21(19-20):2651-60.

- Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen TN, Binz H. Induction of protective immunity in rodents by vaccination with
10 a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. *Virology.* 1997, 230(2):155-66.

Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. *J Gen Virol.* 2001, 82:2881-8.

- 15 Robinson RF, Nahata MC. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. *Am J Health Syst Pharm.* 2000, 57(3):259-64. Review. Erratum in: *Am J Health Syst Pharm* 2000 Apr 1;57(7):699.

Sambrook J., Fritsch EF, Maniatis T. *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989

- 20 Schmidt U, Beyer J, Polster U, Gershwin LJ, Buchholz UJ. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. *J Virol.* 2002, 76(23):12355-9.

- Siegrist CA, Plotnicky-Gilquin H, Cordova M, Berney M, Bonnefoy JY, Nguyen
25 TN, Lambert PH, Power UF. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. *J Infect Dis.* 1999, 179(6):1326-33.

- Spehner D, Drillien R, Lecocq JP. Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus
30 fusion gene. *J Virol.* 1990, 64(2):527-33.

Srikiaikhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia

during experimental murine respiratory syncytial virus infection. *J Exp Med.* 1997a, 186(3):421-32.

Srikiatkhachorn A, Braciale TJ. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. *J Virol.* 1997b, 71(1):678-85.

Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc Natl Acad Sci U S A.* 1992, 89(22):10847-51.

Van Gennip HG, van Rijn PA, Widjojatmodjo MN, Moormann RJ. Recovery of infectious classical swine fever virus (CSFV) from full-length genomic cDNA clones by a swine kidney cell line expressing bacteriophage T7 RNA polymerase. *J Virol Methods.* 1999, 78(1-2):117-28.

Wyatt LS, Moss B, Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. *Virology.* 1995, 210(1):202-5.

SEQUENCE LISTING

<110> NVI Nederlands Vaccin Instituut
 <120> A Respiratory Syncytial Virus with a genomic deficiency complemented in trans
 <130> P210823 pct
 <160> 33
 <170> PatentIn version 3.1

<210> 1
 <211> 15213
 <212> DNA
 <213> Human respiratory syncytial virus

<400> 1
 acgagaaaaa aagtgtcaaa aactaatatc tcgtagttta gttaatatac atataaacca 60
 attagatttg ggttttaaatt tattcctcct agatcaaaat gataatttta ggattagtto 120
 actagaagtt attaaaaaatt atataattat taatttttaa taactataat tgaatacagt 180
 gttagtgtgt agccatggga atttttatta taagattttt gttcattatt cattatggaa 240
 gttgtataac aaactacctg tgattttaat cagtttttta agttcattgg ttgtcaagct 300

	gtttaacaat tcacttagat gaggatatgt agattctacc atatataaat gattatagtt	360
5	taattctgtt gatctgaaat ttaaaacatg attgaaccac tttaagatgt tcatgtgctt	420
	atgattttata agttttattgc tgaaaacttc attacgtcca gctatagaat aagatagtat	480
	atctccacta acaacactct ttagttttaga caatgcagta ttaattcctt tttttgttat	540
10	agggtaacaa agaaagggtg tcaaaactct aatatttgca tcaatagact cttttatcagc	600
	cttcttaggc atgatgaaat ttttggttct tgatagtatc aatttagcat ttgtactac	660
15	attaaatact gggaacacat ttgcaggacc tattgtaagg actaagtaaa cttcagatcc	720
	ctttaactta ctgcctaagc atacataagt ttttaataata gttatgttgt ctaatttgaa	780
	atcgatatca tcttgagcat gatattttac tattaacgta catttattaa ctgaagaaca	840
20	gtacttgcat tttcttacct gcttgctcca ctctattata attttattcc agttgactgt	900
	tacaggcaat tcagcatcac agacaaaag gctgataggt tcagcaaact ttatatgtaa	960
25	ataagaccaa tgaatgttgt tggttgcac tgtagcagga atggtc aaat tttcaccata	1020
	atcaatgttg atatgtccat tgtacagcct taaaaactca attggtaaac tatgatcatt	1080
	acaatctttc agacttctgt aaatatatct tataacagga tgaagttcca ctactgtacg	1140
30	caataataaa ttccctgctc cttcacctat gaatgtata caattaggat ctttaatttt	1200
	aaggctctttt aaaatatact ctatactaatt tttaaacct gtagaactaa atacaaaatt	1260
35	gaatctatta atatgatgcc aaggaagcat gcaataaagt gatgtgctat tgtgtactaa	1320
	agatatttga tgagaagtag tagtgtaaag ttggttagat ttggtgtat tacctgaatg	1380
	atctataatt ttatcaatca caaccgtagg aaataaatta tacaatctt gtctgctgta	1440
40	attggttcta atcattgtag acgatttaat aagcttctta ttagataaca atggtaacat	1500
	tattgagtca acatttttac ctatacaata gtcattcagt gtctttttat cattactttt	1560
45	aacoggattg gttagtatat tttctagggt ttctgggtga ggatgatata atttggtgta	1620
	attactttct aattcagaat tagcaatcct tatatgttta gttaatagat gattattatc	1680
	tgagaagtta taattaatgt aaaaaagatt agaagtataa aattcatcat tgaatttggtg	1740
50	tttattttta atgtatatcc tatctatatt tatcaatccc attctaacaa gatctatata	1800
	agttaataatt gctttcatat gtgttgatg ataacttatg ttaacaaccg aagggaacac	1860
55	tgtgaattct gctacattaa gacgtttaag aaaccatagt ttgaagctat gacatccttt	1920
	tactctatgt aaacttgcat cctggctaag aatgtatttg ataacttttt gttctaaaaa	1980
	taccttagac atagacttcc aataactact gtctattaat tccaatacac ataggagatc	2040
60	tgaagtatto atatcacact ccagctttgc tctgctgtaa cttttatgaa aacacaagag	2100
	atatgtctta taagcattga agaaaacttt caaattaatg aacatatgat cagttatata	2160
65	tccctctccc caatcttttt caaaaatacc tttagaatct ttcataagtt gtataatcag	2220
	aatccaatgt ccagctaaat tagtacttaa aatgtaagta ttatgaaaat agtcagatat	2280
	cttatgcgcc aatattaaat tagaattaac attagatcca gattttagtg ttttattact	2340

	taagaataat tccacatatt gagtcaaaact tattttgtct ggtaaaaaaca tatgctgttt	2400
5	ttgtatcact tgttttaact tgtgaatata aacatcacct gtgaatatgg gaggtttcat	2460
	caaatgtatc tcattaagct tgggtatgag aataattctg ttaggacata cattagtaaa	2520
	ttgttctact actgacatta agctaaggcc aaagcttata cagttttgga atactatata	2580
10	aatatcttca tcaccatact tttctgttaa tatgcgatta atagggctag tatcaaagt	2640
	atagtttgta gttctatagg ctggtattga tgcagggaat tcacatggtc tactactgac	2700
15	tgtagaaga tgcaaatagt taacacttaa atattgtgga aataatTTTT tggccttctc	2760
	atatgctaac ccaagagttc ctatgctaag ttctccatg aattcatcct tgttatctat	2820
	agatgcatac acccaatcca attttgctaa tagatctatt tgatctctct gttttttggt	2880
20	taaaacttgt ctattataaa ctggcattgt tttttctct tgtgtagatg aaccaacca	2940
	tggtttagtg ggtcctctct caccacgtgt taaactgtg acattatatt tctctatgat	3000
25	tatgccacta gctatagtgc ttgttgtata ttgatgtcc attgtataca tgatactggg	3060
	tgatgtaaca ccaactatat tggataaaga ccaagatctt tctctaact atttacttaa	3120
	ttcagtaata cttaggtttt ccatactcaa tatttctctt ttatctctgt tacaacttaa	3180
30	tggtaatatc cttataagca agttatgtt ttctctcctc atctcagtg ctctatcaat	3240
	atctgttaag tctatggcag aagtcttttc cagtatgta gttatagatt ttgtaccgga	3300
35	tataagattt actattttct ctgctttata aaagggtaaa ctttcataaa caactcttag	3360
	ccpgtgagga tatgtaggtt ctatattttg cataatatca ttaagatcta tctctgtagt	3420
	ggtatagtgt tgtgcacttt tggagaatat tttgtttgga gctgtgctca aaacctcagt	3480
40	aactgccagt ctattgattt cactagtaat tttagcttgc ctctcagatc ctaaagcttg	3540
	aggatctctc atcaatgtta caaatccagc attaggggtt ttgtcaaacy tgattatgca	3600
45	tgtaagaat ttattcaatc tatcatctga cagatcttga agtttatctt ttaaatcatg	3660
	gtttgtataa taactaagta tgaacacaga gtgaactata gcctctgtga gaaaatcagg	3720
	agttcttcta tagaaacttc gatataacaa gttgggatca ccaccaccaa ataacatggg	3780
50	caaatccata tacaatgtta atgctgtatc aatattatca agattaaaaa aggtttttaa	3840
	gtgttttaga acctttaata tgtccaaata taatttgttg ttacataatg catgattttt	3900
55	tagttgtaaa gcaatttgat tatataacca tacatttcta aatattaaac tgcataatag	3960
	actttcacct ctatattcta attcttgtgt caaactacct atagattcta gactcacttt	4020
	gaaatcatca agtatagtgt ttatccacgg tccactctt aggaactttct ttatactagc	4080
60	tgggtaatat acacogttat gttggatcgt tttactcata aattgcataat ctcttgatat	4140
	ataagtctca gttcctttta atttgtggcc tatgcctgca tactctttat acagtaattt	4200
65	gagactgttt aatgctagca aataatctgc ttgagcatga gtttgacctt ccatgagctc	4260
	gactggttta cttatatcta ttgattgatt gtcaccatta attaaagcag taattgagaa	4320
	ttccctttg agagatatta gatctaatag tgatatagct tctatggctc atagtttttg	4380

	acaccaccct	tcgataccac	ccatatgata	tctatataat	ccactttgct	catctacatt	4440
5	gttaagatct	acaatatgat	ccottatata	gggggggtgca	tgccatatatg	tgcatattat	4500
	tgtgacatga	ggaatagtta	aatgtaacca	ggaaaataga	gattgtacac	catgcagttc	4560
	atccagtaca	tcactacaaa	tacatgatgt	ttcatatcga	aatgcttgat	tgaatttgct	4620
10	gagatctgtg	atgatagago	acttactaat	gtaattgttg	taattatcat	tgtaacgatt	4680
	tgatttggtta	cttattcctg	ctttcaatto	taatatttto	tgtagttcta	gatcaccata	4740
15	tcttgtaaga	ctttcagggg	aaaattgtaa	aatgttttca	gctatcattt	tctctgctaa	4800
	tatttgaaot	tgtctgaaca	ttcctgggtg	cattgcaaac	attctaccta	cactgagttc	4860
	tctttcttta	cctgtcaatg	ataccacatg	attaggggtg	ttaagataac	tttgattaac	4920
20	tacacagttg	tataaatcac	attcattgaa	tttgttatct	cttaaatagt	actotaatac	4980
	tcttcttgat	ttatcactct	cagagaatct	taacttttca	tgttctatat	aattttgtat	5040
25	gtgtgacggc	atataatttc	tagggaaact	agtccatatt	aaatttttag	gagggtgat	5100
	agccttatca	tttatgatca	tttcgagatc	cactttttta	ggcaatcgaa	actcccgata	5160
	gaaacgtagt	cctgatagaa	caatcaaato	tctttctgta	agttccaaca	aggaaggata	5220
30	agtgttttagt	ttatagtaag	ttaaccatct	taagggtaaa	acaatggcat	tccttaaagt	5280
	aggccatctg	ttgtaattat	ttacaaaacc	ttttataatt	ctatatataa	aggcacctct	5340
35	taacatactc	aaactgctta	acaagtaaaa	tttggctctg	ttgcaattaa	ctttaacagc	5400
	atccatggct	tgtctttcat	ctaccattgg	gtgtccaaat	attctgaaca	aaaaatataa	5460
	ttcactcaga	ttgttaaggt	tattgtcacc	tgcaagctta	attaatttta	ggaacttact	5520
40	taatagaatt	atccatctgc	catttattat	attatcggat	actgtcttat	ctaataatgt	5580
	atgacatact	ottgatagca	gatttttctg	agctttatta	gcagcatctg	tgatgttggt	5640
45	gagcatacta	ttataaaacc	gtttttctgaa	ttgatcttct	tctgttatat	ttaaaattag	5700
	agacataata	aatccctcta	cctcttttat	tatgtagaac	ccctcattgt	gaaatagttt	5760
	tagtatacaa	totccataaa	ggaataattg	tgtcaagata	acattattga	atccacatct	5820
50	taagcctaag	cttttattta	atgtgttcaa	acagttacta	atccatgtaa	tcaaacaac	5880
	atttaatot	ctaaggctaa	tatctttcca	tgtcaagaat	tgattatagg	ttgtcacagt	5940
55	aattcttttg	agttccttat	gataaaactat	acaacatata	tgattcaaaa	taaattggaa	6000
	tccattaaga	gtatgattat	ctatcaatat	aaaaccatgg	ttttttacct	cactagatcg	6060
	atactgtggt	aatatgctgt	ttaattttgt	gtataaatta	aaccaatgta	ttaacatga	6120
60	tggaggatgt	tgcatcgaac	acattaattt	cttcaagagt	gttgttttga	ttgtatcttt	6180
	ttgttttgta	gagtgatttt	tgtctgcttt	aagatgagat	tgattatcct	taacagctaa	6240
65	aagtatatca	tctttgatta	tggttgtaat	aactgagttg	tcttcatctt	gtccattggt	6300
	ggatttaato	ttgtcttttt	ctttaagccc	cagttttattc	agtatagcat	agactttgac	6360
	atcactaatt	tctatagctc	ttcttattat	ctttttaagt	aaattagtg	tagtaatctg	6420

	ttctgacgag gtcatactct tgtatgtcat aagtaatgac tgaaaatagg taggttcttc	6480
5	tattttttatt tcacctttat gatacttaga tattaaggac tgtgttatat ttagtttctt	6540
	tagattttatg tgttctatta atggattttg tctactaatt aagttggtat aatcattttt	6600
	gagataagga ccattgaata tgtaacttcc taaagcatta cattctgaga aagaaataac	6660
10	acctttttaa taactatcag ttagataaac attagcagaa tttccattaa taatgggac	6720
	cattttgtcc catagcttga attgtttgag ttaatagttt gatgatgtgg taagcattag	6780
15	gattgagtgt tatgacacta atatatatat tgtgtatata tcatcattaa tacctagatg	6840
	ttgtagaaaa ttttgagttg catcaatcaa gtcttgagag gtccaatgga tttcattgaa	6900
	tggttgattc ggtgagtata tatggttatt ttggttgggt tgattgatat atagtgtgtt	6960
20	tttttgatta tacatagtaa ctctacaact acttgttatt agtatggaat ttatactaca	7020
	aggataattg tcaggtagta tcattatttt tggcatgggc gtccgtatca ctaacagttg	7080
25	attcttttgg gttattgatg gttatgctct tgtggatata caatgtgttt ttgatggttt	7140
	tcttcaatac atctgccggc aatcttttta acagatgaat agtttgttta ttgttttcc	7200
	tgttgcttcc aatatatgat atgacagtat tgtacactct tatcttgggt gaatttggct	7260
30	cttcattgtc ccttagtttt ttgatgtcat cactgttgag ttcagtgagg agtttgctca	7320
	tggcaacaca tgctgattgt ttagttatat tatttattga tcctatataa ctctctagca	7380
35	ctccaactac accgagggca tactcttctg ttctgtccaa ctctgcagct ccacttattt	7440
	ctgataaagt atctatgctt ttatccatag acttaagtat tctgtttaac ataaaatttt	7500
	gtottacaag cagtgcattg ggtggccatt caaaataatt atgactaaaa tggcacctct	7560
40	tgccattcaa gcaatgacct cgaatttcaa atttgcaagg attccttctg gacatatttg	7620
	cccagttct tatttttaca aatagtaagt taatctggta ttcaattggt ttatataact	7680
45	ataaaatagg aatctactta aatagtgtaa gtgagatggt ttatagatga aagttgtgat	7740
	gaagttcaaa ttttaagaaa atccaatgat agatgggtta tctatggta gatagtgaac	7800
	cattgtaaga atatgattag gtgctatttt tattcagcta ctaaatgcaa tattgtttat	7860
50	accactcagt tgatccttac ttagtgtgac tgggtgtgct ctggccttgc aatatagaag	7920
	cagtccaact gcaattaatg ataacaatat tactataatc actataatta tagtagttat	7980
55	catgatattt gtggtggatt taccagcatt tacattatgt aataattcat ctgattttacg	8040
	aataaatgct agactctggt taatcttctc attgacttga gatattgatg catcaaatto	8100
	atcagagggg aacactaatg ggtcatagaa atttattatt gggtcacctt ttacatagag	8160
60	acttttgcct tottgcttat ttacataata taatgtatta cctacagaca cagtatccac	8220
	cccttatttt gatacataat cacaccgtt agaaaatgtc tttatgatcc cagatttttt	8280
65	attggatgct gtacatttag ttttgccata gcatgacaca atggctccta gagatgtgat	8340
	aacggagctg cttacatctg tttttgaagt cataattttg caatcatatt tgggggtgaa	8400
	tatgtcaatg ttgcagagat ttacctcact tggtaatgtt aaactgttca ttgtatcaca	8460

	aaataccccga tttgattgaa ctttacatgt ttcagcttgt ggggaagaaag atactgatcc	8520
5	tgcatgtgca cagtaccatc ctctgtcggg tcttggttaag cagatgttgg acccttcctt	8580
	tgtgttggtt gtacatagtg gggatgtgtg cagtttccaa caagggtgat ctattacacc	8640
	atatagtggg aattgtacta catatgctaa gacttcctcc tttattatgg acatgataga	8700
10	gtaactttgc tgtctaacta tttgaacatt gttggacatt aactttttct gatcatttgt	8760
	tataggcata tcattgatta atgataataa ttcactatta gttaacatat aagtgcctac	8820
15	agggtgtagt acacotgcat tgacactaaa ttccctggta atctctagta gtctgttgtt	8880
	cttttgttgg aattctatca cagtttcaat gtttgatatg ctgcagcttt gcttgttcac	8940
	aataggtaac aactgtttat ctatatagtt tttgagatct aacactttgc tgggtaagac	9000
20	actgactcca tttgataagc tgactacagc cttgtttgtg gatagtagag cacttttgat	9060
	tttgttcact tccccttcta ggtgcaagac cttggatacg gcaatgccac tggcgattgc	9120
25	agatccaaca cctaacaaaa agccaagaaa tcttcttttc ctttcttgc ttaatgttac	9180
	attgggtgtt ttggcattgt tgagtgtata attcataaat cttggtagtt ctctcttggc	9240
	tcgattgttg gctgctggtg tgctttgcat gagcaattgt aattctgtta cagcattttt	9300
30	atatttatct aattctgtt ttatcaattt taccttagcg tctgttccat tacacttatt	9360
	ttccttgata gtacttaatt ctatagttat aacactagta taccaaccag ttcttagagc	9420
35	gctaagatag cccttgctaa ctgcactgca tgttgattga tagaattctt cagtgatgtt	9480
	ttgactggaa gcgaaacaga gtgtgactgc agcaaggatt gtggtaatag catttgtttt	9540
	gaggattggc aactccattg ttatttgccc catagttagt tttgattctg tttgatttgg	9600
40	tcattggctt ttgcaataat acgcttttta atgactactg gtttgttgtg ttggatggag	9660
	atagagattg tgataggtac tcggatgttg tatagacttg tgaagggtct ggattgcctt	9720
45	cggagggtgt tgagtggaga gtttcctttt gacttgtgtg ttctggattt cctgtggtgt	9780
	tggagggtgag cagtgtagtt ctgatgtttg ttttgggtgt gttgatggtt ggcttttctg	9840
	tgggcctggt ggttaagtgt tccttttggt ttgtgggttg aggtttgaga tcttttttgg	9900
50	ttgtcttgat ggttgggttt cttgtgggtt tgggtgggtt tttctttcca ggttttttgt	9960
	ttggtattct tttgcagatg gccagcaag ttggattgtt gctgcatatg ctgcagggtg	10020
55	caaagttgaa cacttcaaag tgaaaatcat tatttgggtt gttttgttgt ttgttttggc	10080
	gttgttttgt ggtgggcttg ctgggttgta tttgggttgt tgttgtgttt ttggtottga	10140
	ctgttgtgga ttgtgggtt gacttagcac ttggtgttgt tgaagctagt gtggtgggtg	10200
60	gttgtgatgt agtttcggac agattggaga ggctgattcc aagctgggga ttctgggtga	10260
	ggtatgttgg ggttgtgttc ttgatctggt ttgttgcac ttgtatgatt gcagtgtttg	10320
65	gtgtgacttt gtggtttgcc gaggetatga atatgatggc tgcaattata agtgaagttg	10380
	agattatcat tgccaaaata gataatgtga tttgtgctat agatttaaga ttttaactgt	10440
	ataagcacga tgatatgaat aatagatgat tgagagtgtc ccaagtcctt tctagtgtct	10500

5 tggcggcgcg ttggtccttg gttttggaca tgtttgcatt tgccccaatg ttgttggttg 10560
 tcttaatat ttagttcatt gttatgacta ttttctaatt aactacttta tggtatagat 10620
 gatggccttg atggtgagac gttgatgtgg ttttgtgaag aggtgagggg agttcactta 10680
 caaatgcaag gttactgttt tgagctatca gattgggtgaa tgctatgtat tgactcgagc 10740
 10 tcttggttagc tcaaagggtt tggtatggaa tatgttatat tcgcagagtt tgttttagtat 10800
 tgcaatcatg atggagatta tgattagcaa agagattatt gttggttatca tgtgtattag 10860
 tgtaaagtaa ggccagaatt tgcttgagaa ttctattggt atggatgtat tttcatttgg 10920
 15 ttgattttgt ctaattgtgt gactagtcta tggtgacaga tggtgtgatt agttggattc 10980
 ctctcaatga ttatttgccc catgtggatt ttttattaac ttatttgagt actggatctg 11040
 20 atgaacaatg acttgggatg atctgagact cctgatgagt tttgtttgat tggttgaacc 11100
 acaaaggggt ggtgattacg attgtgaagt gaagaatgta ggtagaaagt ttgtatgaat 11160
 caactcactg atgtagagga aaaagggtta tcttccatgg gtttgattgc aaatcgtgta 11220
 25 gctgtgtgct tccaatttgt tgtaacataa tatatacttt ctttttctaa gtaagctcca 11280
 agatctacta tgaattgact ttgtggcttt atgtatttga atgctccttt gttgtcagtc 11340
 30 actgtgatga ctaacagtaa tcttgagtaa gggatgattt ttgcatttgt aatagcattt 11400
 ttgaattcag tggttggtat attttcaagt gtgttcagat ctttatttct gacactgatg 11460
 gatctcaggt atggttggtat tatgactttt tttgatgtta ctatattttc aaattcacat 11520
 35 aaagcaatga tgtcatgtgt tgggttgagt gttttcatag tgagatcttt aactgtagtt 11580
 aacataatgt ttgattttag gcatgttaga ctgcatgcct taatttcaca gggtgtgggt 11640
 40 acatcatatg ccagcttgct tctttcatcc aaggacacat tggcacatat ggtaaatttg 11700
 ctgggcattt gogctagcac tgcacttctt gagtttatca tgactcttaa tgatggtccc 11760
 ttgggtgttg atatttggtt cactagtata ttgacattgg ctagtctctt tataagtaaa 11820
 45 tctgctggca tggatgattg gaacatgggc acctatattg taagtgatgc aggatcatcg 11880
 tctttttcta ggacattgta ttgaacagca gctgtgtatg tggagccctc gtgaagtttg 11940
 50 ttcacgtatg tttccatatt tgccccatct ttttttgtaa ctatagtatc gattttttcc 12000
 gggtggctag ttttggattg gctggttggt tttttggctg gttggttaat cggcaaatgg 12060
 atgtttgggt ggatgggtga attggtttgt ttgttagtct tctattgatg ttgtgttttg 12120
 55 atgtgcagat aggtagctaa tcagaaatct tcaagtgata gatcattgtc actatcattc 12180
 ccttccaaca ggttgttcaa tttttctgat gttgattga gagacaattc atctgatgtg 12240
 60 tcttttgcca tcttttcact ttctcattc ctgagctctg ccatagcttc tagtctgtca 12300
 ttggtcatta atgcttcagt tctgattttt tctatcattt cttctcttaa accaaccatg 12360
 gcatctctta taccatcccg agcagatgta ggtcctgcac tcgctaactac taatgtgtga 12420
 65 agcattcccta gtatttcact taatttctca tcaatcctat ctaactctgc tgttatatta 12480
 tcgtttgtct ggtcattaat ttcttcatat gaatagctag attcttcttc attgttatca 12540

aatgtttcta tggtttcttt gtatagtttt gaaaagggat tatcacttgg cgtagggtct 12600
 5 tctttgaaac ttactagagg ttttctttga taattgggct tgttcctac agtatcatct 12660
 gtctcattta ttgggtttat aatggttgaa tttgatgtta tagggctttc tttgggtact 12720
 tctatatcta ttgagttgac agatatgata ctatcttttt tcttgggac tttgggtgat 12780
 10 gtgaatttgc cctttattga ttctaggaat ttggtggctc tgttgtttgc atctctotcca 12840
 tggaattcag gagcaaactt ttccatgatg ttttatttgc ccattttttt ttattaactc 12900
 15 aaagctctac atcattatct tttggattaa gttgatgttt gatagcctct agttctctctg 12960
 ctgtcaagtc taatacactg tagttaatca caccattttc tttgagttgt tcagcatatg 13020
 cttttgcagc atcatataga tcttgattoc ttggtgtacc tctgtattct ccatttatgc 13080
 20 ctaggccagc agcattgcct aatactacac tagagaagtg aggaaattga gtcaaagata 13140
 ataattgatgc ttttgggttg ttcaatatat ggtagaatcc tgcttctcca ccaatttttt 13200
 gggcatattc atacacctcc acaacctgtt ccatttctgc ttgcacacta gctgtctcta 13260
 25 acataatatt ttttaactgat tttgctaaga ccccccaccg taacatcact tgcctctgac 13320
 cataggcatt cataaacaat cctgcaaaga tcccttcaac tctactgcca cctctggtag 13380
 30 aagattgtgc tataccaaaa tgaacaaaa catctataaa gtgaggatat ttttcaaaca 13440
 ctbcatagaa gctgtttgct atatccttgg gtagtaagcc tttataacgt ttcatttcat 13500
 35 tttttaagac attattagct ctccaatca cagctgtaag accagatcta tcccctgctg 13560
 ctaatttggg tattactaat gccgtatac ataattatt catcccacaa tcaggagagt 13620
 catgcctgta ttctggagcc acctctacca tttcttttag catttttttg taggattttc 13680
 40 tagattctat ctcaatgttg atttgaattt cagttgttaa gcttgctaatt gttaacactt 13740
 caaatttcat ttctttacca ttaattgtct gacgatgtgt tgttacatcc actccatttg 13800
 45 ctttaacatg atatcccgca tctttgagta tttttatggg gtcttctctt cctaattctag 13860
 acatagcata taacatacct attaacccag tgaatttatg attagcatct tctgtgatta 13920
 atagcatgcc acatagcttg ttgatgtgtt tctgcacatc ataattagga gtgtcaatgc 13980
 50 tatctcctgt gctccgttgg atagtgtatt tgctggatga cagaagttga tctttgttga 14040
 gtgtatcatt caacttgact ttgctaagag ccatttttgt atttgcccc tctttcatct 14100
 55 tatgtctctc cttaatttta aattactata attttcaggc tccattttga ctatggagtg 14160
 tgattgtgca tgaagttatt atttcagatt gtttgaatct tgttttgaaa ttcattggatt 14220
 gagatcatac ttgtatatta tgggtgtgtg cttagtaggc ttaatgccaa tgcattctaa 14280
 60 gaacccatca tgattgataa atattggcat agggaaagtg coataatttg tgttgtattc 14340
 agtatatttt ttatatttag tgcttccac tttgtgcaat agtttcattt catagttgac 14400
 65 caggaatgta aatgtggcct gtctttcatc aagttttctc actatgcatt catgatttat 14460
 caagtatata aatctatgtg ttatgatgtc tctggttagt gatgttatta tagtctcaag 14520
 tgacaatggg ctcatgtcag tgatcatcag tctttgtggg gtggtatcat tgtgtgttgt 14580

	gtccatggtt gggtcagctt agttgattta ttggcccat ttttatcttc tgtcaagttt	14640
5	tatattaact aatgggtgta gtgacattga ttgctagtt gatatttatt ataatttatg	14700
	gattaaggtc aaatccaagt aattcagata attgattcat ataattggtc attgttgaat	14760
	cacttagttt ttgggagaat ttaatttcac aattgtcatc tattaggcca ttaggttgag	14820
10	agcaatgogt taattccatc atttcccata tataacctcc attttgtaat actggcattg	14880
	ttgtgaagtt ggatttcact acaatattat tattagggca aatatcacta cttgtaataa	14940
15	catgcacaaa tacaatgcc a ttcaatttaa ttgtatgtat aactgcctta gccaaagcat	15000
	tagttaactg tattaatttg tcagtatagc atgttatatt taacaatgct acttcatcat	15060
	tgtcaaacia attttgcaat ctaactttta tcatactcaa tgagttgctg cccatctcta	15120
20	accaaaggag taaaatttaa gtggtactta tcaaattctt atttgccca tttttttggt	15180
	ttacgcaagt ttgttgtagc cattttttog ogt	15213
25	<210> 2	
	<211> 47	
	<212> DNA	
	<213> Artificial	
	<400> 2	
30	aattggtagc taatacgact cactataggg acgagaaaa aagtgtc	47
	<210> 3	
	<211> 27	
	<212> DNA	
	<213> Artificial	
35	<400> 3	
	ttaaagcgt catcaacta ttaactc	27
	<210> 4	
	<211> 29	
40	<212> DNA	
	<213> Artificial	
	<400> 4	
	aattacggt taagcattag gattgagt	29
45	<210> 5	
	<211> 33	
	<212> DNA	
	<213> Artificial	
	<400> 5	
50	ttaaggatcc gcgcgtatt attgcaaaaa gcc	33
	<210> 6	
	<211> 27	
	<212> DNA	
55	<213> Artificial	
	<400> 6	
	aattgcgcgc tttttaatga ctactgg	2
	<210> 7	
60	<211> 38	
	<212> DNA	
	<213> Artificial	
	<400> 7	
65	ttaaggatcc gtacgttggg gcaaatgcaa acatgtcc	38
	<210> 8	
	<211> 28	
	<212> DNA	

<213> Artificial
 <400> 8
 ttaacccggg gcaaataaaa catcatgg 28

5 <210> 9
 <211> 46
 <212> DNA
 <213> Artificial
 <400> 9
 10 aattcgtagc tattgttagt cttaatatct tagttcattg ttatga 46

<210> 10
 <211> 32
 <212> DNA
 15 <213> Artificial
 <400> 10
 aattcccgga atttttttta ttaactcaaa gc 32

<210> 11
 <211> 43
 <212> DNA
 <213> Artificial
 <400> 11
 20 ttaaaccctgg taagatgaaa gatggggcaa atacaaaaat ggc 43

<210> 12
 <211> 38
 <212> DNA
 <213> Artificial
 <400> 12
 30 aattggatcc accaggtctc tccttaattt taaattac 38

<210> 13
 <211> 65
 <212> DNA
 <213> Artificial
 <400> 13
 35 aattcttaag ggaccgcgag gaggtggaga tgccatgccg acccagcga aaaaatgcgt 60
 acaac 65

<210> 14
 <211> 28
 <212> DNA
 <213> Artificial
 <400> 14
 40 gtccgacctg ggcacccgaa ggaggacg 28

<210> 15
 <211> 26
 <212> DNA
 <213> Artificial
 <400> 15
 50 acgtctctct tcggatgccc aggtcg 26

<210> 16
 <211> 68
 <212> DNA
 <213> Artificial
 <400> 16
 55 tcgtccactc ggatggctaa gggaataacc ccttggggcc tctaaacggg tcttgagggg 60
 ttttttgc 68

<210> 17
 <211> 71
 <212> DNA
 <213> Artificial
 <400> 17
 65 ggccgcacaaa aaccctcaa gaccggttta gaggcaccaa ggggttattc ccttagccat 60

	cagagtgagac g	71
	<210> 18	
	<211> 29	
5	<212> DNA	
	<213> Artificial	
	<400> 18	
	ttaactcgag ttattcatta tgaaagttg	29
10	<210> 19	
	<211> 27	
	<212> DNA	
	<213> Artificial	
	<400> 19	
15	aattggtacc gggacaaaat ggcaccc	27
	<210> 20	
	<211> 27	
	<212> DNA	
20	<213> Artificial	
	<400> 20	
	ttaactctaga ttgtaactat attatag	27
	<210> 21	
25	<211> 31	
	<212> DNA	
	<213> Artificial	
	<400> 21	
	aattggatcc ggggcaaata aatcatcatg g	31
30	<210> 22	
	<211> 29	
	<212> DNA	
	<213> Artificial	
35	<400> 22	
	aattggatcc ggggcaaata caagatggc	29
	<210> 23	
	<211> 31	
40	<212> DNA	
	<213> Artificial	
	<400> 23	
	ttaactcgag attaactcaa agctctacat c	31
45	<210> 24	
	<211> 31	
	<212> DNA	
	<213> Artificial	
	<400> 24	
50	aattggatcc ggggcaaata tgtcacgaag g	31
	<210> 25	
	<211> 34	
	<212> DNA	
55	<213> Artificial	
	<400> 25	
	ttaactctaga tcaggtagta tcattatattt tgge	34
	<210> 26	
60	<211> 26	
	<212> DNA	
	<213> Artificial	
	<400> 26	
	ttaactctaga agtaactact ggcgtg	26
65	<210> 27	
	<211> 44	
	<212> DNA	

	<213> Artificial	
	<400> 27	
	aattggatcc ggggcaaata caaacatgtc caaaaacaag gacc	44
5	<210> 28	
	<211> 32	
	<212> DNA	
	<213> Artificial	
	<400> 28	
10	aattccatgg ggtccaaaac caaggaccaa cg	32
	<210> 29	
	<211> 31	
	<212> DNA	
15	<213> Artificial	
	<400> 29	
	aaaagtatac ttaatgtgat ttgtgctata g	31
	<210> 30	
20	<211> 44	
	<212> DNA	
	<213> Artificial	
	<400> 30	
	ttttgtatac tggcagctat aatctcaact tcacttataa ttgc	44
25	<210> 31	
	<211> 27	
	<212> DNA	
	<213> Artificial	
30	<400> 31	
	aatttctaga tttttaatga ctactgg	27
	<210> 32	
	<211> 31	
35	<212> DNA	
	<213> Artificial	
	<400> 32	
	ttaatctaga cgttacgcga acgcgaagtc c	31
40	<210> 33	
	<211> 41	
	<212> DNA	
	<213> Artificial	
	<400> 33	
45	aattaagctt accatggaca cgattaacat cgctaagaac g	41

Claims

1. A virion of a pneumovirus comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby
5 the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion.
2. A virion according to claim 1, whereby the pneumovirus is a Respiratory
10 Syncytial Virus.
3. A virion according to claims 1 or 2, whereby the gene codes for a G attachment protein.
- 15 4. A virion according to any one of claims 1-3, whereby the mutation causes the virus produced from only the viral genome to lack the protein.
5. A virion according to claim 1, whereby the mutation comprises deletion of the sequence coding for the protein.
20
6. A method for producing pneumoviral virions, the virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for (in vivo) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein
25 in a form and in an amount that is required for infectivity of the virion, the method comprising the steps of:
 - (a) infecting a culture of a first host cell with a pneumovirus comprising a viral genome that has the mutation, whereby the host cell comprises an expression vector which directs expression in the host cell of the protein in a form and in an amount that is
30 required for infectivity of the virion; and,
 - (b) recovery of the virions from the infected host cell culture.

7. A method according to claim 6, whereby the pneumovirus that is used to infect the culture of a first host cell culture, is produced the method comprising the steps of:
- (a) providing to a second host cell one or more expression vectors which direct expression in the host cell of:
- 5 i) a viral genomic RNA that has a mutation in a gene coding for a protein that is essential for (in vivo) infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity;
- ii) a pneumoviral polymerase enzyme complex and optionally one or more further viral proteins; and,
- 10 (b) culturing the second host cell whereby the virions are produced.
8. A method according to claim 7, which further comprises amplifying the virions produced by the second host cell by one or more further cellular infection steps employing host cells which are the same or different from the second host cell.
- 15 9. A method according to claims 7 or 8 wherein the viral genomic RNA is transcribed from a viral DNA copy that is under the control of a bacteriophage DNA-dependent RNA polymerase promoter and whereby the host cell is provided with an expression vector which directs expression in the host cell of the bacteriophage DNA-
- 20 dependent RNA polymerase.
10. A method according to claim 9 whereby the bacteriophage DNA-dependent RNA polymerase is the T7, T3 or SP6 polymerase.
- 25 11. A method according to any one of claims 7-10, whereby the pneumoviral polymerase enzyme complex at least includes the L, P, N proteins.
12. A method according to any one of claims 7-11, whereby one or more further viral proteins is a pneumoviral matrix membrane protein, preferably the M2-1 protein.
- 30 13. A method according to any one of claims 6-12, whereby the pneumovirus is a Respiratory Syncytial Virus.

14. A method according to any one of claims 6-13, whereby the gene coding for the protein that is essential for infectivity is a gene coding for a G attachment protein.

5 15. A composition comprising a virion as defined in any one of claims 1-5, or obtainable in a method as defined in any one of claims 6-14, and a pharmaceutically acceptable carrier.

16. Use of a virion as defined in any one of claims 1-5 for the manufacture of a medicament for the prevention or treatment of a pneumoviral infection.

10

17. A use according to claim 16, the medicament is a preparation for intranasal administration.